Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
QED Therapeutics
AddedFeb 17, 2024
UpdatedJun 18, 2026
QED Therapeutics

QED Therapeutics

Acquired

QED Therapeutics, a BridgeBio Pharma subsidiary, focuses on precision medicine for FGFR-driven disorders.

HQ
Palo Alto, CA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Founded as a subsidiary of BridgeBio Pharma, QED Therapeutics is a biotechnology company dedicated to precision medicine for FGFR-driven disorders. The company’s core mission is to develop meaningful treatment options for individuals with skeletal dysplasias and other FGFR-driven conditions. QED Therapeutics is primarily focused on the development of infigratinib, a targeted therapy currently being evaluated in preclinical studies for achondroplasia and other FGFR-driven tumors.

Notable figures affiliated with QED Therapeutics include key scientists and executives from BridgeBio Pharma. The company has garnered significant attention and investment due to its innovative approach to treating rare genetic disorders. Among its key achievements is the advancement of infigratinib through various stages of clinical development. QED Therapeutics has made a considerable impact by addressing unmet medical needs and improving the quality of life for patients with FGFR-driven conditions.

QED Therapeutics - Similar Companies

Quentis Therapeutics logo

Quentis Therapeutics

Alphina Therapeutics logo

Alphina Therapeutics

AIxCrypto logo

AIxCrypto

BridGene Biosciences logo

BridGene Biosciences

BridgeBio Pharma logo

BridgeBio Pharma

bridgebio.com

Quanta Therapeutics logo

Quanta Therapeutics

quantatx.com

Edison Pharmaceuticals logo

Edison Pharmaceuticals

QED Labs logo

QED Labs

Encoded Therapeutics logo

Encoded Therapeutics

PAQ Therapeutics logo

PAQ Therapeutics

paqtx.com

Nested Therapeutics logo

Nested Therapeutics

nestedtx.com

KSQ Therapeutics logo

KSQ Therapeutics

ksqtx.com

BioQ Pharma logo

BioQ Pharma

bioqpharma.com

iQure Pharma logo

iQure Pharma

iqurepharma.com

Qlaris Bio logo

Qlaris Bio

qlaris.bio

QED Therapeutics - Quick Facts

Who are QED Therapeutics' competitors?

Companies similar to QED Therapeutics include Quentis Therapeutics, Alphina Therapeutics, AIxCrypto and BridGene Biosciences.

When was QED Therapeutics founded?

QED Therapeutics was founded in 2018.

Where is QED Therapeutics' headquarters located?

QED Therapeutics' headquarters is located in Palo Alto, CA, US.

When was QED Therapeutics' last funding round?

QED Therapeutics' most recent funding round was for $65M (USD) in January 2018.

How much has QED Therapeutics raised to-date?

As of Jan 30, 2018, QED Therapeutics has raised a total of $65M (USD).

QED Therapeutics - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Biotechnology
Tags
  • SaaS
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 23 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 513200Software Publishers
  • 541500Computer Systems Design and Related Services
  • 510000Information
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 513000Publishing Industries
  • 325410Pharmaceutical and Medicine Manufacturing
  • 513210Software Publishers
  • 541510Computer Systems Design and Related Services
  • 325412Pharmaceutical Preparation Manufacturing
  • 541511Custom Computer Programming Services
SIC
  • 2800Chemicals And Allied Products
  • 7300Business Services
  • 8000Health Services
  • 2830Drugs
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 7371Computer Programming Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified